Attovia Therapeutics

Attovia Therapeutics is a biotechnology company based in Fremont, California, with 25 employees. The company is focused on developing a pipeline of biotherapeutics, initially targeting immune-mediated diseases and oncology. They utilize their proprietary ATTOBODY platform, a novel biologics platform that generates small format biparatopic binders. These binders offer picomolar affinity, exceptional specificity, and accelerated target internalization, resulting in a "glue-like" binding effect. The unique design of ATTOBODIES allows for fast tissue penetration, easy engineering into bispecifics, and tunable half-life, ranging from hours to weeks. This translates to a wider range of targetable diseases and epitopes, potentially resulting in stronger efficacy and a faster speed to response compared to traditional treatment approaches. To learn more about Attovia Therapeutics and its innovative ATTOBODY technology, visit their website at attovia.com.